The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression
Open Access
- 1 January 2020
- journal article
- research article
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 26 (1), 16-20
- https://doi.org/10.18553/jmcp.2020.26.1.16
Abstract
DISCLOSURES: Funding for this summary was contributed by the Laura and John Arnold Foundation, National Institute for Health Care Management, California Health Care Foundation, Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Healthcare, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER’s annual policy summit is supported by dues from Aetna, America’s Health Insurance Plans, Anthem, AstraZeneca, Allergan, Alnylam, Biogen, Blue Shield of California, Cambia Health Services, CVS Caremark, Editas, Express Scripts, Genentech, GlaxoSmithKline, Harvard Pilgrim Health Care, Health Care Service Corporation, HealthPartners, HealthFirst, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinkrodt Pharmaceuticals, Merck, Novartis, National Pharmaceutical Council, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare. Agboola, Fazioli, and Pearson are employed by ICER. Touchette reports grants from ICER during the course of this work and personal fees from Monument Analytics, unrelated to this work. Atlas has nothing to disclose.Keywords
This publication has 10 references indexed in Scilit:
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled StudyAmerican Journal of Psychiatry, 2019
- EFFICACY AND SAFETY OF ESKETAMINE NASAL SPRAY PLUS AN ORAL ANTIDEPRESSANT IN ELDERLY PATIENTS WITH TREATMENT-RESISTANT DEPRESSIONAmerican Journal of Geriatric Psychiatry, 2019
- UNDERSTANDING THE CHALLENGES, NEEDS, AND QUALITIES OF FRONTOTEMPORAL DEMENTIA FAMILY CAREGIVERSAmerican Journal of Geriatric Psychiatry, 2019
- A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric DisordersAmerican Journal of Psychiatry, 2017
- Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysisCurrent Medical Research and Opinion, 2017
- Pharmacological approaches to the challenge of treatment-resistant depressionDialogues in clinical neuroscience, 2015
- A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013Psychiatric Services, 2014
- The increasing burden of depressionNeuropsychiatric Disease and Treatment, 2011
- Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D ReportAmerican Journal of Psychiatry, 2006